Subscribe to RSS
DOI: 10.1055/s-0035-1557235
Quetiapine in children and adolescents with subaverage IQ
Subject Editor:
Publication History
02 June 2004
25 July 2004
Publication Date:
29 July 2015 (online)
Abstract
A retrospective study was conducted to assess the effectiveness and tolerability of quetiapine in children and adolescents with subaverage replaced with IQ. Through a chart review conducted in a specialized outpatient clinic, five patients were identified (three males, two females; mean age = 16 ± 3.7 years); three were judged to be responders. Patients were included if concomitant medications remained unchanged during the titration and maintenance periods. Treatment duration was 20 ± 4 weeks; dose was 620 ± 205 mg/day. Improvements were observed in the conduct and hyperactivity subscales of the Conners Parent Rating Scale, routinely completed by the same caregiver. No differences were noted in anxiety, inattention, learning, and psychosomatic subscales. None of the patients discontinued the medication due to adverse events, but two experienced sedation. Quetiapine may be beneficial for treating associated symptoms of mental retardation; however, prospective and controlled studies are needed to assess further its efficacy and safety.